Gilead stock rises on more upbeat forecasts, while COVID drug sales slide

Shares of Gilead Sciences Inc. rose after the drugmaker reported third-quarter results that topped expectations and boosted its full-year profit and sales outlook.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.